Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

This is a Phase 1 (a and b), first in human (FIH), single-arm, open-label, multicenter study to evaluate the safety, tolerability and efficacy of GCC2005 in the treatment of patients with relapsed/refractory (R/R) NK or T-cell malignancies who have received at least two prior lines of therapy.

Trial Details

NCT ID

NCT06699771

Phase

PHASE1

Sponsor

GC Cell Corporation

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

GCC2005
Cyclophosphamide
Fludarabine

Locations (sample)

Seoul, Seoul, South Korea|37.566,126.9784
Seoul, Seoul, South Korea|37.566,126.9784
Seoul, Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

Participants with relapsed or refractory CD5+ NK and T-cell originated malignancies (per WHO classification 2017).
Participants with relapsed or refractory disease previously treated with two or more lines of standard chemotherapies and there is no longer any tr…
According to the Lugano classification, Participants having lesion/nodules ≥ 1 with diameter longer than 1.5 cm for nodal lesions and longer than 1…
Participant has a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →